Thomas Barnetche

Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study

Marie Kostine, L. Rouxel, Thomas Barnetche et al. · Annals of the Rheumatic Diseases · 2017 · 293 citations

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

Jérôme Avouac, Élodie Drumez, É. Hachulla et al. · The Lancet Rheumatology · 2021 · 290 citations · Full text

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +9

A mutation in the 3′-UTR of the <i>HDAC6</i> gene abolishing the post-transcriptional regulation mediated by hsa-miR-433 is linked to a new form of dominant X-linked chondrodysplasia

Delphine Simon, Benoît Laloo, Malika Barillot et al. · Human Molecular Genetics · 2010 · 93 citations · Full text

Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events

Marie Kostine, Eleonora Mauric, Alice Tison et al. · European Journal of Cancer · 2021 · 87 citations · Full text

Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance

Marc Scherlinger, Vincent Germain, Céline Labadie et al. · Joint Bone Spine · 2017 · 81 citations

Clinical Effectiveness, Clinical Translation, Patient Safety +8